Core Viewpoint - Rebio Biotech-B (06938) is recognized as a leader in the small RNA field in China, with significant market potential and a robust pipeline of drug candidates [1] Company Overview - Rebio Biotech has a fully integrated technology platform, particularly in delivery technology, and is often referred to as the "Chinese version of Alnylam" [1] - The company has six self-developed siRNA drugs currently in clinical trials, targeting seven indications, with four of them in Phase 2 trials [1] - Over 20 preclinical assets are also in development [1] Market Potential - By 2026, approximately 26.7 million people globally will be affected by thrombotic diseases, with the anticoagulant drug market projected to reach around $70 billion [1] - The company's pipeline targets FXI, effectively mitigating bleeding risks associated with existing drugs, and siRNA offers long-lasting and safe treatment options [1] Competitive Landscape - The company's pipeline has first-in-class (FIC) potential and has already entered Phase 2 clinical trials, specifically in a Phase 2a trial for coronary artery disease [1] - The company plans to initiate Phase 2b clinical trials within the year [1] - Phase 1 clinical data indicates that the company's product demonstrates superior anticoagulant effects with strong safety profiles, showing no serious adverse events related to the drug [1] - The peak potential of the product is estimated to reach a scale of $10 billion [1]

Core Viewpoint - The company is a leading player in the small nucleic acid field in China, with self-developed technology that possesses global competitiveness, focusing on siRNA drug development for chronic diseases and has established strategic partnerships with major pharmaceutical companies [1] Group 1: Company Overview - The company was founded in 2007 and specializes in the research and development of siRNA drugs, particularly in chronic disease areas with significant patient populations [1] - It is one of the few companies globally with proprietary intellectual property and clinically validated GalNac delivery technology, enhancing its market position [1] - The RiboGalSTAR technology platform has a strategic partnership with Boehringer Ingelheim, potentially leading to milestone payments of up to €2.36 billion [1] Group 2: Market Potential - The global small nucleic acid drug market is projected to grow from $5.7 billion in 2024 to $54.9 billion by 2033, with a CAGR of 21%-29% from 2024 to 2034, indicating a rapid growth trajectory [1] - The company aims to convert its technological barriers into commercial value as a leading player in the domestic small nucleic acid sector [1] Group 3: Product Pipeline and Clinical Trials - The FXI siRNA product has the potential to tap into a market space worth billions, targeting thrombotic diseases affecting approximately 26.7 million people globally, with an anti-thrombotic drug market valued at around $70 billion [2] - The company’s pipeline includes several candidates with first-in-class (FIC) potential, currently in Phase 2 clinical trials, including treatments for coronary artery disease [3] - The APOC3 siRNA has initiated Phase 2 clinical trials in the EU, ranking among the top two globally, addressing a significant patient population of 860 million with high triglycerides [3] - The PCSK9 siRNA has exclusive rights in Greater China, maximizing global value, while the HBV siRNA aims for functional cure and is in Phase 2 global MRCT clinical trials [3] Group 4: Financial Forecast and Investment Rating - The company’s current revenue primarily comes from milestone payments from collaborations, with four candidate drugs in Phase 2 clinical trials [4] - Assuming approval by 2030 and a 50% revenue-sharing model with partners, the company is valued using the FCFF method, with a target price of RMB 114.6 / HKD 128.3, indicating approximately 50% upside from the current stock price of HKD 86.8 [4]

Core Viewpoint - Dongwu Securities initiates coverage on RiboBio (06938) with a "Buy" rating and a target price of HKD 128.3, highlighting its leadership in the domestic small RNA field and the potential of its core product targeting FXI to become a billion-dollar FIC drug [1] Group 1: Company Overview - RiboBio, established in 2007, focuses on siRNA drug development for chronic diseases and possesses globally competitive proprietary GalNac delivery technology [1] - The company has a strategic partnership with Boehringer Ingelheim, potentially earning up to €2.36 billion in milestone payments, enhancing its growth ceiling [1] - RiboBio's RiboGalSTAR technology platform is complemented by RiboOncoSTAR and RiboPepSTAR platforms, positioning the company at the forefront of global small RNA drug development [1] Group 2: Market Potential - The global small RNA drug market is projected to grow from USD 5.7 billion in 2024 to USD 54.9 billion by 2033, with a CAGR of 21%-29% from 2024 to 2034, indicating a rapid growth trajectory [2] - RiboBio, as a leading player in the domestic small RNA sector, is expected to translate its technological barriers into commercial value [2] Group 3: Product Pipeline and Clinical Progress - The FXI siRNA product has the potential to tap into a market space worth billions, addressing the clinical pain points of existing anticoagulant drugs while demonstrating long-lasting effects and safety [3] - The company is advancing its FXI siRNA into Phase 2b clinical trials, following promising Phase 1 results showing strong anticoagulant effects without severe adverse events [3] - RiboBio's pipeline includes several promising candidates targeting various chronic diseases, with significant patient populations and market opportunities [4] - The APOC3 siRNA has entered Phase 2 clinical trials in the EU, while the PCSK9 siRNA has exclusive rights in Greater China, maximizing global value [4] - The HBV siRNA is in Phase 2 global MRCT clinical trials, aiming for functional cure in a market with approximately 280 million infected individuals [4]

Core Viewpoint - Dongwu Securities initiates coverage on RiboBio (06938) with a "Buy" rating and a target price of HKD 128.3, highlighting its leadership in the domestic small RNA field and the potential of its core product targeting FXI to become a billion-dollar FIC drug [1] Group 1: Company Overview - RiboBio, established in 2007, focuses on siRNA drug development for chronic diseases and possesses globally competitive proprietary GalNac delivery technology [1] - The company has a strategic partnership with Boehringer Ingelheim, potentially earning up to €2.36 billion in milestone payments, enhancing its market ceiling [1] - RiboBio's RiboGalSTAR technology platform is complemented by RiboOncoSTAR and RiboPepSTAR, positioning the company at the forefront of global small RNA drug development [1] Group 2: Market Potential - The global small RNA drug market is projected to grow from USD 5.7 billion in 2024 to USD 54.9 billion by 2033, with a CAGR of 21%-29% from 2024 to 2034, indicating a rapid growth trajectory [2] - RiboBio aims to convert its technological barriers into commercial value as a leading player in the domestic small RNA sector [2] Group 3: Product Pipeline and Clinical Progress - The FXI siRNA product has the potential to tap into a market space worth billions, addressing the clinical pain points of existing anticoagulant drugs while demonstrating long-lasting effects and safety [3] - The company is advancing its FXI siRNA into Phase 2 clinical trials, with expectations to initiate Phase 2b trials within the year [3] - RiboBio's pipeline includes several promising candidates targeting various chronic diseases, with significant global patient populations and market opportunities [4] - The APOC3 siRNA has commenced Phase 2 clinical trials in the EU, ranking among the top two globally, while the PCSK9 siRNA has exclusive rights in Greater China [4] - The HBV siRNA is in Phase 2 global MRCT clinical trials, aiming for functional cure, and the company has multiple candidates for IgAN entering clinical stages [4]

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 114.6 RMB / 128.3 HKD, indicating approximately 50% upside potential from the current stock price of 86.8 HKD [1]. Core Insights - The company is a leader in the siRNA field, focusing on chronic diseases and has developed proprietary delivery technologies with global competitiveness. It has established strategic partnerships, including one with Boehringer Ingelheim, which could yield up to 2.36 billion euros in milestone payments [7][19]. - The global market for small nucleic acid drugs is projected to grow significantly, from 5.7 billion USD in 2024 to 54.9 billion USD by 2033, with a CAGR of 21%-29% [7][43]. - The company's FXI siRNA product has the potential to tap into a market space worth over 10 billion USD, addressing significant clinical needs in the anticoagulant drug market [7][43]. Summary by Sections Company Overview - The company, established in 2007, specializes in siRNA drug development and has built a comprehensive industry chain from drug discovery to commercialization, becoming a global leader in the small nucleic acid drug development field [13][14]. Market Potential - The small nucleic acid drug market is expected to grow rapidly, with siRNA drugs projected to capture a larger market share due to advancements in delivery systems and chemical modifications [43][45]. - The report highlights that the siRNA market is anticipated to grow at a higher rate than ASO drugs, with siRNA drugs expected to account for 44.5% of the market by 2024 [43][45]. Product Pipeline - The company has a robust pipeline with four candidates in Phase 2 clinical trials and over 20 projects in preclinical stages, demonstrating a strong capability to advance multiple assets to clinical development each year [26][24]. - Key products include FXI siRNA, APOC3 siRNA, and HBV siRNA, each targeting significant patient populations and addressing unmet clinical needs [7][29]. Financial Projections - Revenue is expected to grow significantly, with total revenue projected to reach 142.63 million RMB in 2024, reflecting a year-on-year increase of 324,052.27% [1]. - The company anticipates achieving profitability by 2030, with a 50% revenue sharing model with partners [7].

Core Insights - The Hong Kong stock market has seen a strong start in 2026, with eight companies completing their IPOs within just six trading days, including notable firms in the GPU, surgical robotics, and biotechnology sectors [2][3][5] - The initial public offerings (IPOs) have been well-received, with first-day price increases ranging from 8.44% to 109.09%, indicating strong market enthusiasm for sectors like large models, domestic chip alternatives, and surgical robotics [2][3][5] IPO Performance - MiniMax, a key player in the large model sector, achieved a remarkable first-day closing price increase of 109.09%, with a market capitalization reaching HKD 106.7 billion, and was oversubscribed by 1,836.17 times in public offerings [3][5] - Wallen Technology, the first GPU stock in Hong Kong, also performed impressively with a first-day increase of 75.82% [4] - The average first-day increase for the new batch of IPOs was 40.16%, with a cumulative average increase of nearly 62% since listing, reflecting strong market recognition of high-quality hard tech assets [5][6] Market Dynamics - The current IPO market in Hong Kong is characterized by a large backlog of over 300 companies waiting to list, indicating a robust supply pipeline [6] - In December 2025, 32 companies submitted IPO applications, and 26 companies have done so in January 2026 alone, showcasing sustained enthusiasm for new listings [6] Sector Trends - The successful performance of new IPOs has broken the previous trend of "hot IPOs followed by cold market performance," suggesting that the sectors these companies operate in are gaining market confidence [5][6] - Companies like MiniMax and Zhizhu have shown significant cumulative price increases since their IPOs, with MiniMax achieving a total increase of 141.21% and Zhizhu 79.35% [5][6] Regulatory Environment - The Hong Kong Securities and Futures Commission has emphasized the need for high-quality IPO submissions, responding to concerns about the quality of some recent applications [8] - This regulatory focus aims to shift the IPO market from quantity-driven to quality-driven, which may temporarily slow down the listing process for some companies [8]

Core Viewpoint - The listing of Rebio Biotech (6938.HK) on the Hong Kong Stock Exchange marks a significant milestone for China's small nucleic acid drug development, transitioning from "technical accumulation" to "value realization" [1] Group 1: Market Reaction and Financial Performance - The market reacted positively, with Rebio's stock price rising over 29% in pre-listing trading and closing at 82.1 HKD per share on its first day, reflecting strong investor confidence in Chinese innovative pharmaceuticals [1] - Rebio's financial performance shows a strong revenue growth of 56.57% year-on-year, reaching 1.04 million RMB in the first half of 2025, while losses narrowed by 30.94% during the same period [4][5] - The revenue growth is primarily driven by licensing and collaboration agreements with major players like Boehringer Ingelheim and Qilu Pharmaceutical, indicating recognition of its underlying platform technology [4] Group 2: Strategic Development and R&D - Rebio's platform-based R&D approach is transforming the traditional investment model in biotechnology, moving from betting on single molecules to a modular and scalable development strategy [6] - The company aims to advance 2-4 assets to clinical trials annually, leveraging its platform's efficiency and confidence in its development capabilities [6] - Rebio has established a strong competitive barrier through its intellectual property, holding 255 granted patents and 218 pending applications, alongside a GMP-compliant production facility in Jiangsu [7] Group 3: Ecosystem and Global Strategy - Rebio's strategy combines internal development with external collaboration, targeting global diseases with significant patient populations, such as cardiovascular conditions [9] - The company has formed strategic partnerships, such as with Boehringer Ingelheim, to enhance its technology platform's recognition and optimize commercialization efficiency [11] - Establishing a clinical team in Sweden allows Rebio to conduct high-quality clinical trials independently, enhancing global development efficiency and regulatory communication [12] Group 4: Industry Implications - Rebio's listing signifies a shift in the Chinese biotechnology sector from "following innovation" to "source innovation," showcasing its platform-based R&D capabilities and global operational vision [13] - The company is positioned to accelerate its transition from clinical to commercial stages, with the potential for its platform value and pipeline to resonate in the emerging nucleic acid drug era [13]

Group 1: IPO Activities - The first trading week of 2026 saw significant IPO activities in both domestic and international capital markets, marking an active start to the year [2] - The Beijing Stock Exchange approved its first IPO of the year, with Zhoushan Chenguang Electric Motor Co., Ltd. successfully passing the review [2] - Hong Kong's stock market experienced a surge of hard-tech company listings, with companies like Zhipu, Tensu Zhixin, and Jingfeng Medical showing strong performance despite market adjustments [2][5] Group 2: Company Highlights - Zhoushan Chenguang Electric Motor Co., Ltd. plans to raise 399 million yuan, down from an initially proposed 520 million yuan, with funds allocated for high-speed motors and R&D center construction [3] - Guangdong Banzai Chuangke Electric Co., Ltd. aims to raise approximately 400 million yuan, showing significant revenue growth from 10.71 billion yuan in 2022 to an expected 15.1 billion yuan in 2025 [4] - Zhipu, listed on the Hong Kong Stock Exchange, had an opening price of 116.2 HKD, closing at 131.5 HKD, with a total market value of 57.89 billion HKD and a fundraising total of about 4.348 billion HKD [5] - Tensu Zhixin, another new listing, opened at 190.2 HKD, closing at 156.8 HKD, with a total market value of 39.877 billion HKD and raising approximately 3.677 billion HKD [5] - Jingfeng Medical-B, a leader in surgical robotics, saw its stock rise to 56.6 HKD from an initial price of 43.24 HKD, achieving a market value of 21.945 billion HKD and raising about 1.199 billion HKD [6] Group 3: Upcoming IPOs and Filings - Stand Robot and Wanbang Digital Energy have submitted their IPO applications, with Stand Robot being a leader in industrial mobile robot solutions and Wanbang being the largest smart charging equipment supplier globally [8] - Other companies like Tianxiaxiu and Zhong'an Xinke are also in the process of filing for IPOs, focusing on digital marketing and customized AI solutions respectively [9][10] - Chipmaker Xinmai Semiconductor updated its prospectus for a second time, focusing on power management ICs and reporting a revenue increase of 24.3% for the first three quarters of 2025 [10]

Core Viewpoint - Suzhou Rebio Biotechnology Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, becoming the first listed company from Jiangsu in 2023, raising over HKD 1.8 billion to accelerate clinical development and commercialization of innovative therapies [1] Company Overview - Rebio Biotechnology issued 31.61 million shares at an offering price of HKD 57.97 per share [1] - The company is headquartered in Kunshan and has a fully integrated research platform for small nucleic acid drugs, covering all stages from early research to industrialization [1] - Rebio's product pipeline includes seven self-developed drugs that have entered clinical trials, with four currently in Phase II trials [1] Financial and Investment Highlights - The raised capital will be utilized to enhance the clinical development and commercialization processes of its innovative therapies, providing new treatment options for global patients [1] - The company has received significant support from Kunshan, which invested 4 million yuan in its early stages and has continued to support through multiple rounds of financing [1] Industry Context - With Rebio's listing, Kunshan has a total of 51 listed companies, including 35 listed domestically and 16 listed overseas, positioning it among the top cities in China for similar enterprises [1]

Core Viewpoint - Suzhou Rebio Technology Co., Ltd. (Rebio) has successfully listed on the Hong Kong Stock Exchange, with its share price closing at HKD 82.10, reflecting a 41.62% increase from the issue price of HKD 57.97 [1][2]. Group 1: Company Overview - Rebio is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1]. - The total number of shares issued in this offering was 31,610,400 H-shares, with 2,748,800 shares allocated for public offering in Hong Kong and 28,861,600 shares for international placement [2]. Group 2: Financial Details - The total proceeds from the offering amounted to HKD 1,832.45 million, with net proceeds of HKD 1,701.80 million after deducting estimated listing expenses of HKD 130.65 million [2][3]. - The funds raised will be allocated to the research and development of core products RBD4059, RBD5044, and RBD1016, as well as to support pipeline assets in preclinical stages and enhance the technology platform [3]. Group 3: Investor Participation - Key cornerstone investors include Arc Avenue Asset Management, Bright Stone Holdings, and several asset management firms, collectively acquiring 42.5% of the offering [6][7]. - The cornerstone investors' total shareholding includes significant contributions from various funds and insurance companies, indicating strong institutional interest in Rebio [6]. Group 4: Financial Performance Projections - For the fiscal years ending December 31, 2023, and December 31, 2024, Rebio is projected to generate revenues of RMB 0.04 million and RMB 142.6 million, respectively, with net losses of RMB 437.3 million and RMB 281.5 million [8]. - The company anticipates a continued trend of net losses in the upcoming periods, with projected losses of RMB 141.6 million for the six months ending June 30, 2025 [8].